Clinical guideline
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Ann Oncol · 2026
Studies and guidelines: Prostate cancer
43 items with a structured summary · Prostate cancer: the complete guide
Clinical guideline
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
Eur Urol · 2026
Clinical guideline
Screening for Prostate Cancer
JAMA · 2018
About 1.3 deaths per 1000 men screened over about 13 yearsProstate cancer deaths prevented (men aged 55 to 69 years)
Clinical guideline
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
American Journal of Surgical Pathology · 2016
90%Consensus for adopting the new grading system (grade groups)
Clinical trial · Phase 3
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Lancet · 2026
HR 0.72Radiographic progression-free survival
Clinical trial · Phase 3
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
N Engl J Med · 2026
78.9% vs 69.5%8-year overall survival: combination group vs leuprolide alone
Review article
Lutetium-177–PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies
Urologic Oncology: Seminars and Original Investigations · 2026
14 studiesNumber of included studies
Clinical trial
European Study of Prostate Cancer Screening — 23-Year Follow-up
N Engl J Med · 2025
13% lower in the screening groupDeath from prostate cancer (median follow-up 23 years)
Clinical trial · Phase 3
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
Ann Oncol · 2025
24.48 vs 23.13 monthsMedian overall survival (intention to treat)
Clinical trial · Phase 3
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
The Lancet · 2025
HR 0.80 (95% CI 0.66 to 0.96)Overall survival (whole ITT population)
Clinical trial · Phase 3
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
N Engl J Med · 2023
3.1% / 2.2% / 2.9%Death from prostate cancer
Clinical trial · Phase 3
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Lancet Oncol · 2023
42.1 vs 34.7 monthsMedian overall survival
Meta-analysis · Phase 3
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Lancet · 2022
82% vs 69%6-year metastasis-free survival
Clinical trial · Phase 3
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Lancet · 2022
HR 0.54Radiographic progression-free survival — overall population
Clinical trial · Phase 3
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
N Engl J Med · 2022
32.5%Overall survival (reduction in risk of death)
Clinical trial · Phase 3
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
J Clin Oncol · 2022
34% reduction in the risk of deathOverall survival
Clinical trial · Phase 3
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
N Engl J Med · 2021
8.7 vs 3.4 monthsImaging-based progression-free survival
Clinical trial · Phase 3
Olaparib for Metastatic Castration-Resistant Prostate Cancer
N Engl J Med · 2020
7.4 vs 3.6 monthsImaging-based progression-free survival — cohort A
Clinical trial
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Lancet · 2020
92% vs 65%Diagnostic accuracy
Clinical trial · Phase 3
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
N Engl J Med · 2020
19.1 months with olaparib vs 14.7 months with control treatmentMedian overall survival in cohort A (BRCA1, BRCA2 or ATM)
Clinical trial · Phase 3
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Lancet Oncol · 2019
53.3 vs 36.5 monthsMedian overall survival
Clinical trial · Phase 3
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
N Engl J Med · 2019
68.2% vs 47.5%Radiographic progression-free survival at 24 months
Clinical trial · Phase 3
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
N Engl J Med · 2019
8.0 vs 3.7 monthsMedian imaging-based progression-free survival
Clinical trial · Phase 3
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
J Clin Oncol · 2018
57.6 vs 47.2 monthsMedian overall survival (all patients)
Clinical trial · Phase 3
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
N Engl J Med · 2018
23% (219 of 933) vs 49% (228 of 468)Patients with metastasis or death
Clinical trial
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
N Engl J Med · 2018
38% vs 26%Detection of clinically significant cancer
Clinical trial · Phase 3
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
N Engl J Med · 2014
65% vs 14%Radiographic progression-free survival at 12 months
Clinical trial · Phase 3
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
N Engl J Med · 2013
16.5 months vs 8.3 monthsMedian radiographic progression-free survival
Clinical trial · Phase 3
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
N Engl J Med · 2012
18.4 months vs 13.6 monthsMedian overall survival
Clinical trial · Phase 3
Abiraterone and Increased Survival in Metastatic Prostate Cancer
N Engl J Med · 2011
14.8 vs 10.9 monthsOverall survival (median)
Clinical trial
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
N Engl J Med · 2009
5.6% increase in the denosumab group vs 1.0% decrease in the placebo groupChange in lumbar spine bone mineral density at month 24
Observational study
Risk of Fracture after Androgen Deprivation for Prostate Cancer
N Engl J Med · 2005
19.4% in the ADT group vs 12.6% in the group without ADTFracture in men surviving at least five years after diagnosis
Clinical trial · Phase 3
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
N Engl J Med · 2004
0.76 (95% CI 0.62 to 0.94)Hazard ratio for death: docetaxel every three weeks vs mitoxantrone
Observational study
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
N Engl J Med · 2004
449 of 2950 men (15.2%)Overall prevalence of prostate cancer on biopsy
Clinical trial · Phase 3
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Nat Med · 2025
Median not reached in the niraparib + AAP group vs 26 months in the AAP group; HR = 0.52Radiographic progression-free survival (rPFS) in the BRCA subgroup
Clinical trial · Phase 3
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Lancet · 2024
9.30 vs 5.55 monthsRadiographic progression-free survival (primary analysis)
Clinical trial · Phase 3
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
N Engl J Med · 2023
87.3% / 71.4% / 80.0%5-year metastasis-free survival
Clinical trial · Phase 3
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Lancet · 2023
Not reached vs 21.9 monthsRadiographic progression-free survival (primary analysis)
Clinical trial · Phase 3
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
NEJM Evidence · 2022
24.8 months vs 16.6 months (abiraterone + olaparib vs abiraterone + placebo)Median ibPFS (investigator assessment)
Clinical trial · Phase 3
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
JCO · 2019
HR 0.39 (95% CI 0.30–0.50); median not reached vs 19.0 monthsRadiographic progression-free survival (risk of radiographic progression or death)
Clinical trial
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N Engl J Med · 2017
184 in the combination group vs 262 in the ADT-alone groupNumber of deaths
Clinical trial · Phase 3
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
N Engl J Med · 2017
Median not reached vs 34.7 monthsMedian overall survival
Clinical trial · Phase 3
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
N Engl J Med · 2015
57.6 vs 44.0 monthsMedian overall survival
Nothing found.